Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials in cancer via the U.S. National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) for the purposes of ensuring patient safety. Recently there has been a charge toward capturing the patient perspective for those AEs amenable to patient self-reporting via patient-reported outcomes (PRO). The aim of this review was to summarize the empirically reported association between analogous CTCAE and PRO ratings
Purpose The US National Cancer Institute (NCI) Patient-Reported Outcomes version of the Common Termi...
Understanding the potential profile of adverse events associated with cancer treatment is essential ...
Objective: The study sought to describe patient-entered supplemental information on symptomatic adve...
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials...
Systematic capture of the patient perspective can inform the development of new cancer therapies. Pa...
The National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
Symptomatic adverse events (AEs) in cancer trials are currently reported by clinicians using the Nat...
IMPORTANCE Standard adverse event (AE) reporting in oncology clinical trials has historically relied...
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient s...
The National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) reporting...
Purpose There is increasing interest to use patient-reported outcome (PRO) measures to evaluate symp...
Background: The National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminol...
Background: The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Eve...
Purpose—To assess the feasibility of measuring symptomatic adverse events (AEs) in a multicenter cli...
Purpose The US National Cancer Institute (NCI) Patient-Reported Outcomes version of the Common Termi...
Understanding the potential profile of adverse events associated with cancer treatment is essential ...
Objective: The study sought to describe patient-entered supplemental information on symptomatic adve...
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials...
Systematic capture of the patient perspective can inform the development of new cancer therapies. Pa...
The National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
Symptomatic adverse events (AEs) in cancer trials are currently reported by clinicians using the Nat...
IMPORTANCE Standard adverse event (AE) reporting in oncology clinical trials has historically relied...
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient s...
The National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) reporting...
Purpose There is increasing interest to use patient-reported outcome (PRO) measures to evaluate symp...
Background: The National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminol...
Background: The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Eve...
Purpose—To assess the feasibility of measuring symptomatic adverse events (AEs) in a multicenter cli...
Purpose The US National Cancer Institute (NCI) Patient-Reported Outcomes version of the Common Termi...
Understanding the potential profile of adverse events associated with cancer treatment is essential ...
Objective: The study sought to describe patient-entered supplemental information on symptomatic adve...